MarketCap
Facebook
X
Telegram
Emergent BioSolutions Income Statement 2025-2008 | EBS
Brief overview of revenue and earnings at Emergent BioSolutions
The figures are compared over a five-year interval. Emergent BioSolutions reported revenue of $1.6 billion in 2020 and $743 million by 2025. The cumulative result was −52.9%, corresponding to roughly −14% per year. The decline points to a contraction in the scale of the business.
Gross profit was 925 million dollars at the start and 417 million dollars at the end of the period (−55%). The cost base moved against the top-line trend and weighed on the gross result. Comparing the endpoints gives gross margins of 58.7% and 56.1%. The contraction points to pressure from direct costs or weaker pricing power.
EBITDA changed from $489 million to $196 million (−59.9%). There was no major divergence between EBITDA and revenue. The EBITDA share of revenue changed from 31% to 26.4%. Cost pressure reduced operating profitability.
Net profit was 306 million dollars at the start and 52.6 million dollars at the end. The final result developed less favorably than the core business.
Market value was $5.6 billion at the start and $452 million at the end. Lower capitalization reflects weaker investor expectations.
Overall conclusion
Signs of deterioration dominate the five-year picture. Caution is warranted because of a weaker market valuation, a lower gross margin and a softer top-line trend. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Emergent BioSolutions
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
452 M | 448 M | 139 M | 592 M | 2.5 B | 5.63 B | 2.84 B | 3.03 B | 2.08 B | 1.19 B | 1.41 B | 1.05 B | 861 M | 579 M | 610 M | 481 M | 351 M | - |
Shares |
53.5 M | 53 M | 51.2 M | 50.1 M | 53.5 M | 52.7 M | 51.5 M | 50.1 M | 41.8 M | 40.2 M | 38.6 M | 37.3 M | 36.2 M | 36.1 M | 35.7 M | 31.8 M | 30.4 M | - |
Historical Prices |
8.45 | 8.45 | 2.71 | 11.8 | 46.8 | 107 | 55.1 | 62.4 | 48.8 | 30.3 | 36.6 | 28 | 23.9 | 16.1 | 17 | 15.1 | 11.5 | 10.6 |
Net Income |
52.6 M | -191 M | -760 M | -212 M | 220 M | 306 M | 54.5 M | 62.7 M | 82.6 M | 51.8 M | 62.9 M | 36.7 M | 31.1 M | 23.5 M | 23 M | 51.7 M | 31.1 M | - |
Revenue |
743 M | 1.04 B | 1.05 B | 1.12 B | 1.77 B | 1.58 B | 1.11 B | 782 M | 561 M | 489 M | 523 M | 450 M | 313 M | 282 M | 273 M | 286 M | - | - |
Cost of Revenue |
326 M | 681 M | 705 M | 693 M | 748 M | 537 M | 434 M | 322 M | 188 M | 126 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | 318 M | 383 M | 891 M | 925 M | 672 M | 460 M | 365 M | 357 M | 398 M | 332 M | 251 M | 236 M | 231 M | - | - | - |
Operating Income |
100 M | -109 M | -726 M | -170 M | 341 M | 438 M | 114 M | 89.8 M | 124 M | 106 M | 142 M | 89.2 M | 42.8 M | 30 M | 32.1 M | 73.6 M | 40.2 M | - |
Interest Expense |
54.2 M | 11.9 M | 6.4 M | -11.7 M | 34.5 M | 31.3 M | 38.4 M | 9.9 M | 6.6 M | 7.6 M | 6.52 M | 8.24 M | - | 6 K | - | - | 7 K | - |
EBITDA |
196 M | 100 K | -601 M | -26.7 M | 465 M | 489 M | 173 M | 115 M | 167 M | 144 M | 131 M | 90.5 M | 61.8 M | 50.8 M | 41.5 M | 79.5 M | 45.1 M | - |
Operating Expenses |
- | - | - | - | - | - | 558 M | 370 M | 241 M | 252 M | 302 M | 274 M | 208 M | 196 M | 199 M | - | - | - |
General and Administrative Expenses |
186 M | 308 M | 368 M | 340 M | 349 M | 304 M | 274 M | 202 M | 143 M | 144 M | 148 M | 123 M | 87.9 M | 76 M | 74.3 M | 76.2 M | 73.8 M | - |
All numbers in USD currency
Quarterly Income Statement Emergent BioSolutions
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
51.9 M | 53.2 M | 54.2 M | 54.4 M | 53.1 M | 52.6 M | 52.2 M | 51.8 M | 50.7 M | 50.2 M | 50.1 M | 49.9 M | - | 50.7 M | 51.3 M | 53.7 M | 53.6 M | 53.3 M | 53.1 M | 53 M | 52.6 M | 52 M | 51.7 M | 51.6 M | 51.5 M | 51.2 M | 51.2 M | 50.1 M | 49.9 M | 49.6 M | 49.4 M | 41.2 M | 41 M | 40.7 M | 40.6 M | 40.5 M | 40.2 M | 39.5 M | 39.4 M | 38.8 M | 38.5 M | 37.9 M | 37.7 M | 37.5 M | 37.4 M | 36.9 M | 36.6 M | 36.3 M | 36.1 M | 36 M | 35.9 M | 36.2 M | 36.2 M | 36 M | 36 M | 35.9 M | 35.6 M | 35.2 M |
Net Income |
6.8 M | 51.2 M | -12 M | 68 M | 115 M | -283 M | 9 M | -263 M | -261 M | -183 M | - | -87.1 M | - | -3.7 M | - | -32.7 M | 4.6 M | 69.7 M | 185 M | 39.5 M | 92.7 M | -12.5 M | 46.9 M | 43.2 M | -9.5 M | -26.1 M | -3.4 M | 20.9 M | 50.1 M | -4.9 M | - | 33.6 M | 4.62 M | 10.5 M | 37.4 M | 21.3 M | -10.9 M | 3.99 M | 33.3 M | 36.9 M | 14.1 M | -21.5 M | 30.1 M | 21.8 M | 5.03 M | -20.2 M | 15.2 M | 13.5 M | 10.5 M | -8.06 M | 16.1 M | 6.62 M | 7.63 M | -6.83 M | 28.7 M | 1.55 M | 14.2 M | -21.4 M |
Revenue |
156 M | 231 M | 141 M | 222 M | 294 M | 255 M | 300 M | 270 M | 338 M | 165 M | - | 240 M | - | 308 M | - | 329 M | 398 M | 343 M | 583 M | 385 M | 395 M | 192 M | 360 M | 312 M | 243 M | 191 M | 271 M | 174 M | 220 M | 118 M | 194 M | 149 M | 101 M | 117 M | 152 M | 143 M | 91.2 M | 103 M | 160 M | 158 M | 126 M | 63.6 M | 148 M | 138 M | 110 M | 53.9 M | 98.1 M | 89.1 M | 82.4 M | 43.1 M | 94.6 M | 66.6 M | 70.4 M | 50.3 M | 108 M | 58.8 M | 88.1 M | 18.5 M |
Cost of Revenue |
72 M | 85.9 M | 66.9 M | 88.5 M | 123 M | 296 M | 145 M | 177 M | 191 M | 155 M | - | 147 M | - | - | - | - | 228 M | 99.3 M | - | 149 M | 130 M | 76.9 M | - | 108 M | 101 M | 91.8 M | - | 69.3 M | 85.3 M | 54.3 M | - | 44.5 M | 34.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | 161 M | -48 M | 148 M | 87.2 M | 141 M | 3.5 M | - | 75.3 M | - | 142 M | - | - | - | 222 M | - | - | - | - | 77.8 M | 70.7 M | -7 M | -27.4 M | 11.2 M | 21.3 M | 66.8 M | -9.5 M | 53.1 M | 47.8 M | 8.5 M | 14.9 M | 50.9 M | 35.5 M | -2.04 M | 21.2 M | 65.1 M | 63.2 M | 35.1 M | -21.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
10.5 M | 76.5 M | 1.6 M | 49.9 M | 64.5 M | -204 M | 39.8 M | -242 M | -293 M | -148 M | - | -45.3 M | - | 6.4 M | - | -34.7 M | 14.5 M | 95.4 M | 258 M | 61.3 M | 126 M | -11.6 M | 77.8 M | 70.7 M | -7 M | -27.4 M | - | 21.3 M | 66.8 M | -9.5 M | - | 47.8 M | 8.53 M | 14.9 M | - | 35.5 M | -2.04 M | 21.2 M | 49.9 M | 63.2 M | 21.5 M | -28.3 M | 44.6 M | 31 M | 7.86 M | -25.5 M | 23.3 M | 18.1 M | 14.7 M | -13.4 M | 24 M | 9.82 M | 8.65 M | -12.5 M | 46 M | 1.41 M | 20.2 M | -35.5 M |
Interest Expense |
13.9 M | -3.7 M | -3.7 M | 69.7 M | 21.9 M | -2.7 M | 24.3 M | 19.7 M | 28.6 M | 17.9 M | - | 8.5 M | - | 8.2 M | - | 8.4 M | 8.6 M | 8.5 M | - | 7.6 M | 6.4 M | 8.6 M | - | 10.3 M | 9.5 M | 9.6 M | - | 600 K | 1 M | 200 K | - | 1.99 M | 1.8 M | 1.94 M | - | 2.05 M | 1.51 M | 1.52 M | - | 1.64 M | 1.63 M | 1.66 M | - | 1.81 M | 1.72 M | 3.54 M | - | - | 3 K | 11 K | - | - | - | 3 K | - | - | 6 K | - |
EBITDA |
34 M | 149 M | 50.5 M | 75.3 M | 147 M | -147 M | 67.7 M | -230 M | -225 M | -114 M | - | -25 M | - | 37.3 M | - | -20.2 M | 29.6 M | 124 M | 258 M | 147 M | 183 M | 16.6 M | 77.8 M | 154 M | 48.1 M | -800 K | - | 58.4 M | 91.5 M | 2.8 M | - | 77.7 M | 28.6 M | 25.1 M | - | 63.6 M | 15.7 M | 30 M | 49.9 M | 89 M | 38.8 M | -19.8 M | 44.6 M | 55.3 M | 23.2 M | -18.6 M | 23.3 M | 31.7 M | 23.1 M | -9.19 M | 24 M | 17.5 M | 13.6 M | -10.2 M | 46 M | 8.33 M | 24.7 M | -33.3 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 241 M | 250 M | 218 M | - | 152 M | 153 M | 127 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
46.6 M | 38.9 M | 43.7 M | 52.4 M | 76.6 M | 85.9 M | 84.7 M | 86 M | 91.4 M | 100 M | - | 81.8 M | - | 84.8 M | - | 82.1 M | 91.2 M | 80.9 M | - | 75.5 M | 76 M | 69.7 M | - | 65 M | 70.8 M | 65.4 M | - | 42.1 M | 39.5 M | 40 M | - | 34.5 M | 31.9 M | 35.2 M | - | 40.7 M | 35.9 M | 31.7 M | - | 25.8 M | 36.5 M | 34.5 M | - | 30.3 M | 30.6 M | 30.1 M | - | 22 M | 20.5 M | 20 M | - | 19.2 M | 17.9 M | 19.5 M | - | 17.4 M | 20.4 M | 18.2 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Emergent BioSolutions (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Irlanda
Canada
Schweden
France
China
